Global Opioid-Induced Constipation Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030

Opioid-Induced Constipation Market

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Opioid-Induced Constipation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Opioid-Induced Constipation.

The Opioid-Induced Constipation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Opioid-Induced Constipation market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Opioid-Induced Constipation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and regions.

Market Segmentation

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daiichi Sankyo

Prestige

GSK

Shionogi

Methylnaltrexone Bromide

Lubiprostone

Naloxegol

Others

Hospital

Pharmacy

Other

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

Scope of Opioid-Induced Constipation Market Report

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Opioid-Induced Constipation in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 3: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Opioid-Induced Constipation sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.

Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.

Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.

Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.

Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.

Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.

Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 14: Research Findings and Conclusion.

1.1 Opioid-Induced Constipation Product Introduction

1.2 Market by Type

1.2.1 Global Opioid-Induced Constipation Market Size Growth Rate by Type (2019 VS 2023 VS 2030)

1.2.2 Methylnaltrexone Bromide

1.2.3 Lubiprostone

1.2.4 Naloxegol

1.2.5 Others

1.3 Market by Application

1.3.1 Global Opioid-Induced Constipation Market Size Growth Rate by Application (2019 VS 2023 VS 2030)

1.3.2 Hospital

1.3.3 Pharmacy

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

2.1 Global Opioid-Induced Constipation Market Size Estimates and Forecasts

2.1.1 Global Opioid-Induced Constipation Revenue 2019-2030

2.1.2 Global Opioid-Induced Constipation Sales 2019-2030

2.2 Opioid-Induced Constipation Market Size by Region: 2023 Versus 2030

2.3 Opioid-Induced Constipation Sales by Region (2019-2030)

2.3.1 Global Opioid-Induced Constipation Sales by Region: 2019-2024

2.3.2 Global Opioid-Induced Constipation Sales Forecast by Region (2025-2030)

2.3.3 Global Opioid-Induced Constipation Sales Market Share by Region (2019-2030)

2.4 Opioid-Induced Constipation Market Estimates and Projections by Region (2025-2030)

2.4.1 Global Opioid-Induced Constipation Revenue by Region: 2019-2024

2.4.2 Global Opioid-Induced Constipation Revenue Forecast by Region (2025-2030)

2.4.3 Global Opioid-Induced Constipation Revenue Market Share by Region (2019-2030)

3.1 Global Top Opioid-Induced Constipation Manufacturers by Sales

3.1.1 Global Opioid-Induced Constipation Sales by Manufacturer (2019-2024)

3.1.2 Global Opioid-Induced Constipation Sales Market Share by Manufacturer (2019-2024)

3.2 Global Top Opioid-Induced Constipation Manufacturers by Revenue

3.2.1 Global Opioid-Induced Constipation Revenue by Manufacturer (2019-2024)

3.2.2 Global Opioid-Induced Constipation Revenue Share by Manufacturer (2019-2024)

3.3 Global Opioid-Induced Constipation Price by Manufacturer (2019-2024)

3.4 Competitive Landscape

3.4.1 Key Opioid-Induced Constipation Manufacturers Covered: Ranking by Revenue

3.4.2 Global Opioid-Induced Constipation Market Concentration Ratio (CR5 and HHI) & (2019-2024)

3.4.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.5 Global Opioid-Induced Constipation Manufacturing Base Distribution, Product Type

3.5.1 Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution, Headquarters

3.5.2 Manufacturers Opioid-Induced Constipation Product Type

3.5.3 Date of International Manufacturers Enter into Opioid-Induced Constipation Market

3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4.1 Takeda Pharmaceuticals

4.1.1 Takeda Pharmaceuticals Company Information

4.1.2 Takeda Pharmaceuticals Description, Business Overview

4.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered

4.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.1.5 Takeda Pharmaceuticals Opioid-Induced Constipation Sales by Product in 2023

4.1.6 Takeda Pharmaceuticals Opioid-Induced Constipation Sales by Application in 2023

4.1.7 Takeda Pharmaceuticals Opioid-Induced Constipation Sales by Geographic Area in 2023

4.1.8 Takeda Pharmaceuticals Recent Developments

4.2 Bayer

4.2.1 Bayer Company Information

4.2.2 Bayer Description, Business Overview

4.2.3 Bayer Opioid-Induced Constipation Products Offered

4.2.4 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.2.5 Bayer Opioid-Induced Constipation Sales by Product in 2023

4.2.6 Bayer Opioid-Induced Constipation Sales by Application in 2023

4.2.7 Bayer Opioid-Induced Constipation Sales by Geographic Area in 2023

4.2.8 Bayer Recent Developments

4.3 Sanofi

4.3.1 Sanofi Company Information

4.3.2 Sanofi Description, Business Overview

4.3.3 Sanofi Opioid-Induced Constipation Products Offered

4.3.4 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.3.5 Sanofi Opioid-Induced Constipation Sales by Product in 2023

4.3.6 Sanofi Opioid-Induced Constipation Sales by Application in 2023

4.3.7 Sanofi Opioid-Induced Constipation Sales by Geographic Area in 2023

4.3.8 Sanofi Recent Developments

4.4 Mallinckrodt

4.4.1 Mallinckrodt Company Information

4.4.2 Mallinckrodt Description, Business Overview

4.4.3 Mallinckrodt Opioid-Induced Constipation Products Offered

4.4.4 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.4.5 Mallinckrodt Opioid-Induced Constipation Sales by Product in 2023

4.4.6 Mallinckrodt Opioid-Induced Constipation Sales by Application in 2023

4.4.7 Mallinckrodt Opioid-Induced Constipation Sales by Geographic Area in 2023

4.4.8 Mallinckrodt Recent Developments

4.5 Salix (Bausch Health)

4.5.1 Salix (Bausch Health) Company Information

4.5.2 Salix (Bausch Health) Description, Business Overview

4.5.3 Salix (Bausch Health) Opioid-Induced Constipation Products Offered

4.5.4 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.5.5 Salix (Bausch Health) Opioid-Induced Constipation Sales by Product in 2023

4.5.6 Salix (Bausch Health) Opioid-Induced Constipation Sales by Application in 2023

4.5.7 Salix (Bausch Health) Opioid-Induced Constipation Sales by Geographic Area in 2023

4.5.8 Salix (Bausch Health) Recent Developments

4.6 AstraZeneca

4.6.1 AstraZeneca Company Information

4.6.2 AstraZeneca Description, Business Overview

4.6.3 AstraZeneca Opioid-Induced Constipation Products Offered

4.6.4 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.6.5 AstraZeneca Opioid-Induced Constipation Sales by Product in 2023

4.6.6 AstraZeneca Opioid-Induced Constipation Sales by Application in 2023

4.6.7 AstraZeneca Opioid-Induced Constipation Sales by Geographic Area in 2023

4.6.8 AstraZeneca Recent Development

4.7 Progenics Pharmaceuticals

4.7.1 Progenics Pharmaceuticals Company Information

4.7.2 Progenics Pharmaceuticals Description, Business Overview

4.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered

4.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.7.5 Progenics Pharmaceuticals Opioid-Induced Constipation Sales by Product in 2023

4.7.6 Progenics Pharmaceuticals Opioid-Induced Constipation Sales by Application in 2023

4.7.7 Progenics Pharmaceuticals Opioid-Induced Constipation Sales by Geographic Area in 2023

4.7.8 Progenics Pharmaceuticals Recent Development

4.8 Purdue Pharm

4.8.1 Purdue Pharm Company Information

4.8.2 Purdue Pharm Description, Business Overview

4.8.3 Purdue Pharm Opioid-Induced Constipation Products Offered

4.8.4 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.8.5 Purdue Pharm Opioid-Induced Constipation Sales by Product in 2023

4.8.6 Purdue Pharm Opioid-Induced Constipation Sales by Application in 2023

4.8.7 Purdue Pharm Opioid-Induced Constipation Sales by Geographic Area in 2023

4.8.8 Purdue Pharm Recent Development

4.9 Nektar Therapeutics

4.9.1 Nektar Therapeutics Company Information

4.9.2 Nektar Therapeutics Description, Business Overview

4.9.3 Nektar Therapeutics Opioid-Induced Constipation Products Offered

4.9.4 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.9.5 Nektar Therapeutics Opioid-Induced Constipation Sales by Product in 2023

4.9.6 Nektar Therapeutics Opioid-Induced Constipation Sales by Application in 2023

4.9.7 Nektar Therapeutics Opioid-Induced Constipation Sales by Geographic Area in 2023

4.9.8 Nektar Therapeutics Recent Development

4.10 Daiichi Sankyo

4.10.1 Daiichi Sankyo Company Information

4.10.2 Daiichi Sankyo Description, Business Overview

4.10.3 Daiichi Sankyo Opioid-Induced Constipation Products Offered

4.10.4 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.10.5 Daiichi Sankyo Opioid-Induced Constipation Sales by Product in 2023

4.10.6 Daiichi Sankyo Opioid-Induced Constipation Sales by Application in 2023

4.10.7 Daiichi Sankyo Opioid-Induced Constipation Sales by Geographic Area in 2023

4.10.8 Daiichi Sankyo Recent Development

4.11 Prestige

4.11.1 Prestige Company Information

4.11.2 Prestige Description, Business Overview

4.11.3 Prestige Opioid-Induced Constipation Products Offered

4.11.4 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.11.5 Prestige Opioid-Induced Constipation Sales by Product in 2023

4.11.6 Prestige Opioid-Induced Constipation Sales by Application in 2023

4.11.7 Prestige Opioid-Induced Constipation Sales by Geographic Area in 2023

4.11.8 Prestige Recent Development

4.12 GSK

4.12.1 GSK Company Information

4.12.2 GSK Description, Business Overview

4.12.3 GSK Opioid-Induced Constipation Products Offered

4.12.4 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.12.5 GSK Opioid-Induced Constipation Sales by Product in 2023

4.12.6 GSK Opioid-Induced Constipation Sales by Application in 2023

4.12.7 GSK Opioid-Induced Constipation Sales by Geographic Area in 2023

4.12.8 GSK Recent Development

4.13 Shionogi

4.13.1 Shionogi Company Information

4.13.2 Shionogi Description, Business Overview

4.13.3 Shionogi Opioid-Induced Constipation Products Offered

4.13.4 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)

4.13.5 Shionogi Opioid-Induced Constipation Sales by Product in 2023

4.13.6 Shionogi Opioid-Induced Constipation Sales by Application in 2023

4.13.7 Shionogi Opioid-Induced Constipation Sales by Geographic Area in 2023

4.13.8 Shionogi Recent Development

5.1 Global Opioid-Induced Constipation Sales by Type (2019-2030)

5.1.1 Global Opioid-Induced Constipation Sales by Type (2019-2024)

5.1.2 Global Opioid-Induced Constipation Sales Forecast by Type (2025-2030)

5.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2019-2030)

5.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2019-2030)

5.2.1 Global Opioid-Induced Constipation Revenue by Type (2019-2024)

5.2.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2025-2030)

5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2019-2030)

5.3 Opioid-Induced Constipation Average Selling Price (ASP) by Type (2019-2030)

6.1 Global Opioid-Induced Constipation Sales by Application (2019-2030)

6.1.1 Global Opioid-Induced Constipation Sales by Application (2019-2024)

6.1.2 Global Opioid-Induced Constipation Sales Forecast by Application (2025-2030)

6.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2019-2030)

6.2 Global Opioid-Induced Constipation Revenue Forecast by Application (2019-2030)

6.2.1 Global Opioid-Induced Constipation Revenue by Application (2019-2024)

6.2.2 Global Opioid-Induced Constipation Revenue Forecast by Application (2025-2030)

6.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2019-2030)

6.3 Opioid-Induced Constipation Average Selling Price (ASP) by Application (2019-2030)

7.1 North America Opioid-Induced Constipation Market Size YoY Growth 2019-2030

7.2 North America Opioid-Induced Constipation Market Facts & Figures by Country

7.2.1 North America Opioid-Induced Constipation Sales by Country (2019-2030)

7.2.2 North America Opioid-Induced Constipation Revenue by Country (2019-2030)

7.3 North America Opioid-Induced Constipation Sales by Type (2019-2024)

7.4 North America Opioid-Induced Constipation Sales by Application (2019-2024)

8.1 Asia-Pacific Opioid-Induced Constipation Market Size YoY Growth 2019-2030

8.2 Asia-Pacific Opioid-Induced Constipation Market Facts & Figures by Region

8.2.1 Asia-Pacific Opioid-Induced Constipation Sales by Region (2019-2030)

8.2.2 Asia-Pacific Opioid-Induced Constipation Revenue by Region (2019-2030)

8.3 Asia-Pacific Opioid-Induced Constipation Sales by Type (2019-2024)

8.4 Asia-Pacific Opioid-Induced Constipation Sales by Application (2019-2024)

9.1 Europe Opioid-Induced Constipation Market Size YoY Growth 2019-2030

9.2 Europe Opioid-Induced Constipation Market Facts & Figures by Country

9.2.1 Europe Opioid-Induced Constipation Sales by Country (2019-2030)

9.2.2 Europe Opioid-Induced Constipation Revenue by Country (2019-2030)

9.3 Europe Opioid-Induced Constipation Sales by Type (2019-2024)

9.4 Europe Opioid-Induced Constipation Sales by Application (2019-2024)

10.1 Latin America Opioid-Induced Constipation Market Size YoY Growth 2019-2030

10.2 Latin America Opioid-Induced Constipation Market Facts & Figures by Country

10.2.1 Latin America Opioid-Induced Constipation Sales by Country (2019-2030)

10.2.2 Latin America Opioid-Induced Constipation Revenue by Country (2019-2030)

10.3 Latin America Opioid-Induced Constipation Sales by Type (2019-2024)

10.4 Latin America Opioid-Induced Constipation Sales by Application (2019-2024)

11.1 Middle East and Africa Opioid-Induced Constipation Market Size YoY Growth 2019-2030

11.2 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country

11.2.1 Middle East and Africa Opioid-Induced Constipation Sales by Country (2019-2030)

11.2.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2019-2030)

11.3 Middle East and Africa Opioid-Induced Constipation Sales by Type (2019-2024)

11.4 Middle East and Africa Opioid-Induced Constipation Sales by Application (2019-2024)

12.1 Opioid-Induced Constipation Supply Chain Analysis

12.2 Opioid-Induced Constipation Key Raw Materials and Upstream Suppliers

12.3 Opioid-Induced Constipation Clients Analysis

12.4 Opioid-Induced Constipation Sales Channel and Sales Model Analysis

12.4.1 Opioid-Induced Constipation Distribution Channel Analysis: Indirect Sales VS Direct Sales

12.4.2 Opioid-Induced Constipation Distribution Channel Analysis: Online Sales VS Offline Sales

12.4.3 Opioid-Induced Constipation Distributors

13.1 Opioid-Induced Constipation Industry Trends

13.2 Opioid-Induced Constipation Market Drivers

13.3 Opioid-Induced Constipation Market Challenges

13.4 Opioid-Induced Constipation Market Restraints

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

List of Tables

    Table 1. Global Opioid-Induced Constipation Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

    Table 2. Major Manufacturers of Methylnaltrexone Bromide

    Table 3. Major Manufacturers of Lubiprostone

    Table 4. Major Manufacturers of Naloxegol

    Table 5. Major Manufacturers of Others

    Table 6. Global Opioid-Induced Constipation Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

    Table 7. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2023 VS 2030

    Table 8. Global Opioid-Induced Constipation Sales by Region (2019-2024) & (K Units)

    Table 9. Global Opioid-Induced Constipation Sales Forecast by Region (2025-2030) & (K Units)

    Table 10. Global Opioid-Induced Constipation Revenue by Region (2019-2024) & (US$ Million)

    Table 11. Global Opioid-Induced Constipation Revenue Forecast by Region (2025-2030) & (US$ Million)

    Table 12. Global Opioid-Induced Constipation Sales by Manufacturer (2019-2024) & (K Units)

    Table 13. Global Opioid-Induced Constipation Sales Share by Manufacturer (2019-2024)

    Table 14. Opioid-Induced Constipation Revenue by Manufacturer (2019-2024) & (US$ Million)

    Table 15. Opioid-Induced Constipation Revenue Share by Manufacturer (2019-2024)

    Table 16. Key Manufacturers Opioid-Induced Constipation Price (2019-2024) & (USD/Unit)

    Table 17. Ranking of Global Top Opioid-Induced Constipation Manufacturers by Revenue (US$ Million) in 2023

    Table 18. Global Opioid-Induced Constipation Manufacturers Market Concentration Ratio (CR5 and HHI) & (2019-2024)

    Table 19. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2023)

    Table 20. Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution and Headquarters

    Table 21. Manufacturers Opioid-Induced Constipation Product Type

    Table 22. Date of International Manufacturers Enter into Opioid-Induced Constipation Market

    Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans

    Table 24. Takeda Pharmaceuticals Company Information

    Table 25. Takeda Pharmaceuticals Description and Business Overview

    Table 26. Takeda Pharmaceuticals Opioid-Induced Constipation Product

    Table 27. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 28. Takeda Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 29. Takeda Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 30. Takeda Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 31. Takeda Pharmaceuticals Recent Development

    Table 32. Bayer Company Information

    Table 33. Bayer Description and Business Overview

    Table 34. Bayer Opioid-Induced Constipation Product

    Table 35. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 36. Bayer Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 37. Bayer Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 38. Bayer Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 39. Bayer Recent Development

    Table 40. Sanofi Company Information

    Table 41. Sanofi Description and Business Overview

    Table 42. Sanofi Opioid-Induced Constipation Product

    Table 43. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 44. Sanofi Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 45. Sanofi Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 46. Sanofi Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 47. Sanofi Recent Development

    Table 48. Mallinckrodt Company Information

    Table 49. Mallinckrodt Description and Business Overview

    Table 50. Mallinckrodt Opioid-Induced Constipation Product

    Table 51. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 52. Mallinckrodt Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 53. Mallinckrodt Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 54. Mallinckrodt Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 55. Mallinckrodt Recent Development

    Table 56. Salix (Bausch Health) Company Information

    Table 57. Salix (Bausch Health) Description and Business Overview

    Table 58. Salix (Bausch Health) Opioid-Induced Constipation Product

    Table 59. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 60. Salix (Bausch Health) Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 61. Salix (Bausch Health) Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 62. Salix (Bausch Health) Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 63. Salix (Bausch Health) Recent Development

    Table 64. AstraZeneca Company Information

    Table 65. AstraZeneca Description and Business Overview

    Table 66. AstraZeneca Opioid-Induced Constipation Product

    Table 67. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 68. AstraZeneca Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 69. AstraZeneca Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 70. AstraZeneca Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 71. AstraZeneca Recent Development

    Table 72. Progenics Pharmaceuticals Company Information

    Table 73. Progenics Pharmaceuticals Description and Business Overview

    Table 74. Progenics Pharmaceuticals Opioid-Induced Constipation Product

    Table 75. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 76. Progenics Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 77. Progenics Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 78. Progenics Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 79. Progenics Pharmaceuticals Recent Development

    Table 80. Purdue Pharm Company Information

    Table 81. Purdue Pharm Description and Business Overview

    Table 82. Purdue Pharm Opioid-Induced Constipation Product

    Table 83. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 84. Purdue Pharm Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 85. Purdue Pharm Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 86. Purdue Pharm Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 87. Purdue Pharm Recent Development

    Table 88. Nektar Therapeutics Company Information

    Table 89. Nektar Therapeutics Description and Business Overview

    Table 90. Nektar Therapeutics Opioid-Induced Constipation Product

    Table 91. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 92. Nektar Therapeutics Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 93. Nektar Therapeutics Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 94. Nektar Therapeutics Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 95. Nektar Therapeutics Recent Development

    Table 96. Daiichi Sankyo Company Information

    Table 97. Daiichi Sankyo Description and Business Overview

    Table 98. Daiichi Sankyo Opioid-Induced Constipation Product

    Table 99. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 100. Daiichi Sankyo Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 101. Daiichi Sankyo Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 102. Daiichi Sankyo Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 103. Daiichi Sankyo Recent Development

    Table 104. Prestige Company Information

    Table 105. Prestige Description and Business Overview

    Table 106. Prestige Opioid-Induced Constipation Product

    Table 107. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 108. Prestige Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 109. Prestige Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 110. Prestige Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 111. Prestige Recent Development

    Table 112. GSK Company Information

    Table 113. GSK Description and Business Overview

    Table 114. GSK Opioid-Induced Constipation Product

    Table 115. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 116. GSK Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 117. GSK Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 118. GSK Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 119. GSK Recent Development

    Table 120. Shionogi Company Information

    Table 121. Shionogi Description and Business Overview

    Table 122. Shionogi Opioid-Induced Constipation Product

    Table 123. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

    Table 124. Shionogi Sales Proportion of Opioid-Induced Constipation by Product in 2023

    Table 125. Shionogi Sales Proportion of Opioid-Induced Constipation by Application in 2023

    Table 126. Shionogi Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2023

    Table 127. Shionogi Recent Development

    Table 128. Global Opioid-Induced Constipation Sales by Type (2019-2024) & (K Units)

    Table 129. Global Opioid-Induced Constipation Sales Forecast by Type (2025-2030) & (K Units)

    Table 130. Global Opioid-Induced Constipation Revenue by Type (2019-2024) & (US$ Million)

    Table 131. Global Opioid-Induced Constipation Revenue Forecast by Type (2025-2030) & (US$ Million)

    Table 132. Global Opioid-Induced Constipation Sales by Application (2019-2024) & (K Units)

    Table 133. Global Opioid-Induced Constipation Sales Forecast by Application (2025-2030) & (K Units)

    Table 134. Global Opioid-Induced Constipation Revenue by Application (2019-2024) & (US$ Million)

    Table 135. Global Opioid-Induced Constipation Revenue Forecast by Application (2025-2030) & (US$ Million)

    Table 136. North America Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)

    Table 137. North America Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)

    Table 138. North America Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)

    Table 139. North America Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)

    Table 140. North America Opioid-Induced Constipation Sales by Type (2019-2024) & (K Units)

    Table 141. North America Opioid-Induced Constipation Sales by Application (2019-2024) & (K Units)

    Table 142. Asia-Pacific Opioid-Induced Constipation Sales by Region (2019-2024) & (K Units)

    Table 143. Asia-Pacific Opioid-Induced Constipation Sales by Region (2025-2030) & (K Units)

    Table 144. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2019-2030) & (US$ Million)

    Table 145. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2025-2030) & (US$ Million)

    Table 146. Asia-Pacific Opioid-Induced Constipation Sales by Type (2019-2024) & (K Units)

    Table 147. Asia-Pacific Opioid-Induced Constipation Sales by Application (2019-2024) & (K Units)

    Table 148. Europe Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)

    Table 149. Europe Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)

    Table 150. Europe Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)

    Table 151. Europe Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)

    Table 152. Europe Opioid-Induced Constipation Sales by Type (2019-2024) & (K Units)

    Table 153. Europe Opioid-Induced Constipation Sales by Application (2019-2024) & (K Units)

    Table 154. Latin America Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)

    Table 155. Latin America Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)

    Table 156. Latin America Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)

    Table 157. Latin America Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)

    Table 158. Latin America Opioid-Induced Constipation Sales by Type (2019-2024) & (K Units)

    Table 159. Latin America Opioid-Induced Constipation Sales by Application (2019-2024) & (K Units)

    Table 160. Middle East and Africa Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)

    Table 161. Middle East and Africa Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)

    Table 162. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)

    Table 163. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)

    Table 164. Middle East and Africa Opioid-Induced Constipation Sales by Type (2019-2024) & (K Units)

    Table 165. Middle East and Africa Opioid-Induced Constipation Sales by Application (2019-2024) & (K Units)

    Table 166. Opioid-Induced Constipation Key Raw Materials, Industry Status and Trend

    Table 167. Opioid-Induced Constipation Key Raw Materials and Upstream Suppliers

    Table 168. Opioid-Induced Constipation Clients Status and Trend

    Table 169. Opioid-Induced Constipation Typical Clients

    Table 170. Opioid-Induced Constipation Distributors

    Table 171. Opioid-Induced Constipation Market Trends

    Table 172. Opioid-Induced Constipation Market Drivers

    Table 173. Opioid-Induced Constipation Market Challenges

    Table 174. Opioid-Induced Constipation Market Restraints

    Table 175. Research Programs/Design for This Report

    Table 176. Key Data Information from Secondary Sources

    Table 177. Key Data Information from Primary Sources

List of Figures

    Figure 1. Opioid-Induced Constipation Product Picture

    Figure 2. Global Opioid-Induced Constipation Sales Market Share by Type in 2023 & 2030

    Figure 3. Methylnaltrexone Bromide Product Picture

    Figure 4. Lubiprostone Product Picture

    Figure 5. Naloxegol Product Picture

    Figure 6. Others Product Picture

    Figure 7. Global Opioid-Induced Constipation Sales Market Share by Application in 2023 & 2030

    Figure 8. Hospital Examples

    Figure 9. Pharmacy Examples

    Figure 10. Other Examples

    Figure 11. Opioid-Induced Constipation Report Years Considered

    Figure 12. Global Opioid-Induced Constipation Market Size, (US$ Million), 2019 VS 2023 VS 2030

    Figure 13. Global Opioid-Induced Constipation Market Size 2019-2030 (US$ Million)

    Figure 14. Global Opioid-Induced Constipation Sales 2019-2030 (K Units)

    Figure 15. Global Opioid-Induced Constipation Sales Market Share Forecast by Region (2019-2030)

    Figure 16. Global Opioid-Induced Constipation Revenue Market Share by Region (2019-2030)

    Figure 17. Global Opioid-Induced Constipation Sales Share by Manufacturer in 2023

    Figure 18. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

    Figure 19. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2019-2030)

    Figure 20. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2019-2030)

    Figure 21. Opioid-Induced Constipation Average Selling Price (ASP) by Type (2019-2024) & (USD/Unit)

    Figure 22. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2019-2030)

    Figure 23. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2019-2030)

    Figure 24. Opioid-Induced Constipation Average Selling Price (ASP) by Application (2019-2024) & (USD/Unit)

    Figure 25. North America Opioid-Induced Constipation Revenue 2019-2030 (US$ Million)

    Figure 26. North America Opioid-Induced Constipation Sales Market Share by Type (2019-2024)

    Figure 27. North America Opioid-Induced Constipation Sales Market Share by Application (2019-2024)

    Figure 28. Asia-Pacific Opioid-Induced Constipation Revenue 2019-2030 (US$ Million)

    Figure 29. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Region (2019-2030)

    Figure 30. Asia-Pacific Opioid-Induced Constipation Revenue Market Share by Region (2019-2030)

    Figure 31. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Type (2019-2024)

    Figure 32. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Application (2019-2024)

    Figure 33. Europe Opioid-Induced Constipation Revenue Growth Rate 2019-2030 (US$ Million)

    Figure 34. Europe Opioid-Induced Constipation Sales Market Share by Country (2019-2030)

    Figure 35. Europe Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)

    Figure 36. Europe Opioid-Induced Constipation Sales Market Share by Type (2019-2024)

    Figure 37. Europe Opioid-Induced Constipation Sales Market Share by Application (2019-2024)

    Figure 38. Latin America Opioid-Induced Constipation Revenue Growth Rate 2019-2030 (US$ Million)

    Figure 39. Latin America Opioid-Induced Constipation Sales Market Share by Country (2019-2030)

    Figure 40. Latin America Opioid-Induced Constipation Revenue Market Share by Country (2019-2024)

    Figure 41. Latin America Opioid-Induced Constipation Sales Market Share by Type (2019-2024)

    Figure 42. Latin America Opioid-Induced Constipation Sales Market Share by Application (2019-2024)

    Figure 43. Middle East and Africa Opioid-Induced Constipation Revenue Growth Rate 2019-2030 (US$ Million)

    Figure 44. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2019-2030)

    Figure 45. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)

    Figure 46. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Type (2019-2024)

    Figure 47. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Application (2019-2024)

    Figure 48. Opioid-Induced Constipation Supply Chain (Upstream and Downstream Market)

    Figure 49. Global Production Market Share of Opioid-Induced Constipation Raw Materials by Region in 2023

    Figure 50. Opioid-Induced Constipation Distribution Channels

    Figure 51. Global Opioid-Induced Constipation Percentage 2019-2030: Indirect Sales VS Direct Sales

    Figure 52. Global Opioid-Induced Constipation Percentage 2019-2030: Online Sales VS Offline Sales

    Figure 53. Bottom-up and Top-down Approaches for This Report

    Figure 54. Data Triangulation